^
    Back
    Association details:
    Biomarker:MAP2K1 K57N
    Cancer:Melanoma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K- mutated melanoma

    Excerpt:
    Among the low pAKT cohort, two patients had no response to selumetinib. One of these patients had a mutation in the MAP2K1 gene that encodes for a K57N mutation in helix A of MEK1
    DOI:
    10.1073/pnas.0905833106